Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


FDA approves Cabtreo (clindamycin phosphate, adapalene and benzoyl peroxide) topical gel for the treatment of patients 12 year and older – Bausch Health Companies

Written by | 25 Oct 2023 | Dermatology

Bausch Health Companies Inc. and its dermatology business, Ortho Dermatologics, announced that the FDA has approved the New Drug Application for Cabtreo (clindamycin phosphate, adapalene and benzoyl peroxide) Topical Gel 1.2%/0.15%/3.1%, indicated for the topical treatment of acne vulgaris in patients twelve years of age and older.

Cabtreo is the first and only FDA-approved fixed-dose, triple-combination topical treatment for acne. Cabtreo is expected to be available to patients in Q1 2024.

Cabtreo offers three mechanisms of action, combining an antibiotic, retinoid and antibacterial, to
provide a proven, safe and effective treatment.

“While most acne treatments currently available utilize multiple therapies and regimens, we are excited to see that the triple combination in Cabtreoe has resulted in significant treatment success and reduction in both the inflammatory and noninflammatory lesions typically associated with acne,” said Julie C. Harper, MD., Dermatology & Skin Care Center of Birmingham, Birmingham, AL. “With the approval of Cabtreo, physicians can now offer patients an acne treatment that has the potential to be a simple, once daily dosing option.

Cabtreo was studied in two Phase III multicenter, randomized, placebo controlled clinical trials in 363 patients with acne vulgaris. Both studies met all co-primary efficacy endpoints, including absolute change from baseline in inflammatory lesion count, absolute change from baseline in non-inflammatory lesion count, and percentage of patients achieving treatment success (2 grade reduction of the EGSS (evaluators global severity score) from baseline with an EGSS score of clear (0) or almost clear (1)). Combined efficacy results for both trials for Cabtreo achieved approximately 50% treatment success and approximately 75% reduction in both inflammatory and noninflammatory lesions at Week 12.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.